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PHARMACY
Defined Daily Dose (DDD) – A step toward 
Antibiotic Stewardship Program
Dr Ale Zehra, Clinical Pharmacist & 
Dr Kashif Hussain, Specialist, Infectious Disease
Overuse of antibiotics is a global challenge that is leading to antibiotics 
resistance. Pharmacy Services along with Antibiotic Subcommittee of Pharmacy 
and Therapeutic Committee (P&TC) have been working on strengthening the 
surveillance mechanism of antibiotic use in the hospital to achieve Antibiotic 
Stewardship Program (ASP). Qualitative monitoring of antibiotics has been 
in practice and is one of the quality indicators of the Hospital. However, 
quantitative analysis of the antibiotics will be a recent initiative taken by 
Pharmacy, after the approval of Antibiotic Subcommittee. Defined Daily Dose 
(DDD) is a system proposed for quantitative monitoring of the antibiotics 
usage. DDD is recommended tool by World Health Organization (WHO) and 
corresponds to the average daily maintenance dose for a drug’s major indication 
in adults. This system is used to standardize the comparison of antibiotics usage 
between different antibiotics or between different Service Lines of the Hospital.
DDD has been planned to become an indicator of the hospital.  In the meantime, 
Pharmacy is compiling data of DDD with the help of IT and will share it 
with all Service Lines accordingly. Service Lines, Antibiotic Subcommittee 
and Pharmacy will work together to identify the practical gaps that can be 
systematically addressed to optimize the use of antibiotics in the hospital. 
Look-Alike and Sound-Alike Medications - A 
Global Challenge
Saharish Nazar, Assistant Manager Quality Assurance- Pharmacy
Today the effort to provide safe patient care becomes challenging in the complex 
healthcare systems especially with the ever-expanding list of medications. The 
situation becomes even more serious with those medications in particular that 
have been identified as “confusing” or that have “look-alike” or “sound-alike” 
names or packaging. As early as 2001, the Joint Commission published warnings 
about the inherent safety issues related to confusing medication names. In 2012, 
an article in Drug Safety reported that errors caused by drugs name confusion 
ranges from 12- 30%.1 Another study has shown that up to 25% of all medication 
errors are attributed to name confusion and 33% to packaging and labeling 
confusion.2    
Many of these related incidents also occur in Pakistan but dilemma is that they go 
unnoticed and unreported; since at a national level there is no organized system 
and culture to report such incidents. In an institute like Aga Khan University 
Hospital, which has  technology support in the name of Computerized Physician 
Order Entry Systems (CPOE) along with multiple checks before administration 
still we face the problem with look-alike and sound- alike medications and 
incidents get reported.
To “Err is Human”. Solely reliance on human efficiency is inadequate. Rather it’s 
high time that each of us work in collaboration for the safe medication use. Drug 
Regulatory Authority of Pakistan needs to take a leadership role in reviewing 
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current regulations and the problems which endanger public safety. At the same time pharmaceutical companies need to 
be more sensitive to the international standards of labeling, packaging and must develop some processes for assessing 
new drug names during the premarket phase. Hospitals also need to invest in technology to curtail such issues.  The 
Institute of Medicines (IOM) has emphasized that “product naming, labeling, and packaging should be designed for the 
end user — the provider in the clinical environment and/or the consumer.” 
References:
1.  Filik R, Price J, Darker I, Gerrett D, Purdy K, Gale A. The Influence of tall man lettering on drug name confusion. Drug safety.  
 2010 Aug 1; 33(8):677-87.
2.  Berman A. Reducing medication errors through naming, labeling, and packaging. Journal of medical systems. 2004 Feb 1;  
 28(1):9-29.
Beta blockers safe for patients with Asthma or Chronic Obstructive 
Pulmonary Disease
Dr Kashif Hussain, Specialist, Infectious Disease
In 1964, it was noted that propranolol, a non-selective beta blocker, could precipitate severe bronchospasm in patients 
with asthma, especially at high doses. As a result, beta-blockers are often restrained in patient with asthma or Chronic 
Obstructive Pulmonary Disease (COPD). Currently small-scale newer studies  showed that propranolol and other non-
selective beta blockers  like cardioselective beta blockers could increase airway resistance and appear to be safe or even 
beneficial in people with COPD, potentially reducing exacerbations and mortality.1,2
For asthma, cardioselective beta blockers do not seem to precipitate asthma attacks and do not produce clinically 
significant adverse respiratory effects in patients with mild to moderate reactive airway disease. It should not be 
withheld from patients with mild to moderate reactive disease.
Beta blockers are a key component of care for people who have a history of heart attacks or have systolic heart failure. 
Three beta blockers have demonstrated a survival benefit in systolic heart failure; Metoprolol XL, Bisoprolol (cardio 
selective agents) and Carvedilol (non-cardioselective). It is unlikely that the risks of worsening asthma or COPD 
outweigh the potential benefits of beta blocker use.
Beta blockers have not been proven beneficial in randomized trials for stable coronary artery disease (primary 
prevention in people without a previous myocardial infarction or who have risk factors). What’s more interesting is the 
question of whether chronic use of beta blockers might actually improve asthma or COPD, as mounting observational 
evidence suggests. Enough safety data has accumulated that such prospective studies could be done ethically. 
References: 
1. Short PM, Williamson PA, Anderson WJ, Lipworth BJ. Randomized placebo-controlled trial to evaluate chronic dosing effects  
 of propranolol in asthma. American journal of respiratory and critical care medicine. 2013 Jun 15;187(12):1308-14.
2. Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse respiratory effect of acute β-blocker exposure in asthma:  
 a systematic review and meta-analysis of randomized controlled trials. CHEST Journal. 2014 Apr 1;145(4):779-86.
Potential drug-drug interaction of Macrolide and Domperidone | QT 
prolongation
Dr Fahmeen Kinza, Trainee Pharmacist 
Co-administration of Macrolides (for example Azithromycin, Clarithromycin, Erythromycin) and Domperidone may 
result in increased plasma concentrations of domperidone and have an additive effect on the QT interval prolongation.  
Macrolides are potent CYP3A4 inhibitor and QT prolonging drugs. Other cardiac side effects include ventricular 
arrhythmias and sudden death, particularly with domperidone doses greater than 30 mg/day and in patients older than 
60 years. If co-administration is necessary, domperidone should be initiated at the lowest possible dose and titrated with 
caution. Discontinue domperidone if the patient experiences dizziness, palpitations, syncope, or seizure. 
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References:
l Product Information: BIAXIN(R) XL Filmtab(R) oral extended-release tablets, clarithromycin oral extended-release tablets.  
 AbbVie Inc. (per FDA), North Chicago, IL, Sep, 2013.
l Oberg KC & Bauman JL: QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacothera 
 py 1995; 15(6):687-692.
Warfarin therapy monitoring of admitted and post discharge 
patients lead to enhance the patient medication safety 
Dr Ale Zehra, Clinical Pharmacist
The appropriate dose of warfarin is difficult to establish as it is influenced by 
pharmacokinetic and pharmacodynamics factors. Incorrect doses contribute to a high 
rate of adverse effects and hence there is a need to monitor the therapy. To enhance and 
ensure the patient safety, the Drug and Poison Information Center of Pharmacy Services, 
Aga Khan University Hospital, Karachi, Pakistan daily monitor the patients who are on 
warfarin therapy through Computerized Physician Order Entry (CPOE) during hospital 
stay and post discharge following seven days. For this purpose, special form was 
designed by the pharmacist to record all necessary information which is important for 
managing the warfarin therapy. This information includes international normalized ratio 
(INR) periodic monitoring, any bridging therapy, base line INR, renally adjusted dose 
if any, warfarin initial and scheduled dose and date. At the time of discharge Pharmacist 
also counsels the patient regarding diet, INR laboratory monitoring, clinical symptoms 
of high INR etc. If any variation is found in above mentioned parameters, pharmacist 
intervenes to prevent high, low or no base line INR related adverse events. The data for year 2015 to mid-2016 shows 
that approximately  618 in-patients were prescribed warfarin out of which 63 number of patient i.e. an average 10%  of  
in-patients required pharmacist interventions, as their dosage of warfarin was not adjusted according to their INR levels 
either during inpatient stay or post discharge of seven days. Monitoring of warfarin therapy by pharmacist ensures the 
safety of high risk medication to patient.
Influenza (seasonal flu) Vaccination for Health Care Workers
Mehreen Raza, Supervisor, Ambulatory Pharmacy
Seasonal flu is a serious disease that causes illness, hospitalizations, and even deaths every year in the United States (U.S.). 
Annual vaccination is important because influenza is unpredictable, flu viruses are constantly changing and the immunity 
from vaccination declines over time. Since it takes about two weeks after vaccination for antibodies to develop in the body 
that protect against influenza virus infection, it is best that people get vaccinated so they are protected before influenza begins 
spreading in their community. Influenza (flu) among health care personnel (HCP) can result in medical visits and lost work 
days. HCP has the potential to spread flu to patients and other HCP, including those with chronic medical conditions, pregnant 
women, young children, and older people at higher risk of serious flu complications. Influenza vaccination of HCP has been 
shown to reduce the risk of flu in vaccinated HCP and reduce the risk of respiratory illness and deaths in nursing home residents. 
The findings of recent related published literature of Centers for Disease Control and Prevention (CDC) indicate that influenza 
vaccination of health care personnel can enhance patient safety. In this regard CDC, the Advisory Committee on Immunization 
Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC) recommends that all U.S. 
health care workers including physicians, nurses, paramedics, emergency medical technicians, employees of nursing homes and 
chronic care facilities, students in these professions, and volunteers, should receive annual vaccination against influenza. Health 
care providers should offer vaccination by the end of October, if possible. Vaccination should continue to be offered as long as 
influenza viruses are circulating. 
In order to enhance patient safety at national level in Pakistan the policies regarding influenza vaccination for HCP 
should be implemented.
Reference:
l Centers for Disease Control and Prevention. Influenza Vaccination Information for Health Care Workers; United States, 2016.  
 Retrieved from https://www.cdc.gov/flu/healthcareworkers.htm.
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The Aga Khan University Hospital, Karachi
Provide us your Valuable Feedback!
To keep the Pharmacy Newsletter of Aga Khan University Hospital (AKUH) updated we would like to take your valuable feedback. We are grateful 
to you for sparing few minutes of your precious time to complete form by below online link or form can be emailed to you as well. Just drop us an 
email with subject Newsletter Feedback. Email us at:drug.information@aku.edu 
Thank you in advance for your feedback! 
Link: 
https://goo.gl/forms/Ghh1Nc2KY2jEkiUL2
Proud to Report
Pharmacy Services at Aga Khan University Hospital Karachi, Pakistan (AKUH) organized 1st National Medication Safety 
Symposium on December 17th 2016. The theme of symposium was Look-alike, Sound-alike Medications (LASA): A Real 
Threat. Speakers from Drug Regulatory Authority of Pakistan, Hospitals and Pharmaceutical Industry representatives ad-
dressed this issue that how confusing similarities in the brand name and packaging of medications lead to one of the reason 
for medication errors and are of concern worldwide.  AKUH CEO, Hans Kedzierski also spoke to highlight the LASA 
medications in medication error and implementation of bar code technology to enhance patient safety. All representatives 
of Pharmaceutical Industry, Hospitals and Drug Regulatory Authority of Pakistan agreed that there should be a change in 
system to enhance medication safety related to LASA medications. Along with symposium, different stalls and abstracts 
relevant to theme were arranged.
17th December, 1st National Medication Safety Symposium
Symposium Organizing Committee
